Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib maintenance therapy in moderate to severe Crohn's disease
NL-OMON41338Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tofacitinib in Crohn's disease and inflammatory bowel disease (IBD) (3 arms), sponsored by Pfizer. Primary endpoint: Maintenance of clinical response-100 or clinical remission at Week 26. Started Oct 2014; status: active, not recruiting.
02
Drugs
03
Conditions
Crohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON41338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41338.